CS
The startup develops a monoclonal antibody targeting specific immune cell subtypes to enhance cancer immunotherapy. By identifying biomarkers associated with tumor responses, the company aims to create more selective therapies that improve patient outcomes and minimize treatment-related side effects.
Updated 3 months ago
Funding
$12.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops a monoclonal antibody targeting specific immune cell subtypes to enhance cancer immunotherapy. By identifying biomarkers associated with tumor responses, the company aims to create more selective therapies that improve patient outcomes and minimize treatment-related side effects.